Interleukin-22 ameliorates liver fibrosis through miR-200a/beta-catenin

Hu, Bang-li; Cheng, Sheue-yann; Lei, Ronge; Lu, Donghong; Luo, Wei; Qin, Shanyu; Zhou, You; Jiang, Hai‐Xing

doi:10.1038/srep36436

Cited by 42 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accordance with their finding, a previous study of our collaborators demonstrated a positive correlation of miR‐200a with IL‐6, of which increased levels were linked to higher morbidity and mortality rates in HIV patients receiving cART . While the role of miR‐200a in liver fibrosis is controversial in recently published studies, we could not find an association of miR‐200a with liver fibrosis.…”

Section: Discussionsupporting

confidence: 82%

microRNA‐200a: A stage‐dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients

Austermann

Schierwagen

Mohr

et al. 2017

Hepatology Communications

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease contributes to liver‐related mortality and has a high prevalence among patients with human immunodeficiency virus (HIV). The early detection of steatosis could prevent disease progression through life‐style changes. However, as the common serum markers are nonspecific and the gold standard for the detection of nonalcoholic fatty liver disease remains the invasive liver biopsy, its verification is limited. Therefore, the search for novel biomarkers is essential. Several studies have emphasized the role of microRNAs (miRNAs) as biomarkers for certain liver diseases. With our study, we aimed to investigate the potential of miR‐200a as a biomarker for liver injury, fibrosis, and steatosis in HIV patients. The study cohort consisted of 89 HIV patients. Clinical and laboratory parameters were assessed twice, within a median follow‐up period of 12 months. miR‐200a serum levels were determined by real‐time polymerase chain reaction and normalized to spiked‐in RNA (SV40). miR‐200a serum levels showed a significant correlation with the patients' controlled attenuation parameter scores and their body weight at baseline and with alanine aminotransferase serum levels at follow‐up. At baseline, we observed a stage‐dependent increase in miR‐200a serum levels according to the degree of steatosis. More importantly, patients with higher baseline levels of miR‐200a recorded a progression of steatosis at follow‐up. Remarkably, miR‐200a not only reveals a prognostic value for steatosis but possibly also for liver damage and metabolic adaptions as patients with an increase in alanine aminotransferase/aspartate aminotransferase serum levels over time also recorded higher baseline miR‐200a levels. Conclusion: Our study reveals miR‐200a not only to be a stage‐dependent biomarker of steatosis but also to be a predictor of steatosis progression and probably liver cell injury in HIV patients. (Hepatology Communications 2017;1:36–45)

show abstract

Section: Discussionsupporting

confidence: 82%

microRNA‐200a: A stage‐dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients

Austermann

Schierwagen

Mohr

et al. 2017

Hepatology Communications

View full text Add to dashboard Cite

show abstract

“…Consistent with the previous finding that miR-200a is a key player in a variety of disease models associated with fibrosis, including pancreatic fibrosis [ 26 ], liver cirrhosis [ 27 ], and obstructive nephropathy [ 14 ], Xu et al found that miR-200a was down-regulated in TGF-β1-activated pancreatic stellate cells and miR-200a mimic reversed the increased expression of mesenchymal markers vimentin and ECM proteins by activating the PTEN/Akt/mTOR pathway [ 26 ]. In the process of liver fibrosis, Yang et al found that overexpression of miR-200a reduced the SIRT1 expression, consequently preventing activation and proliferation of hepatic stellate cells [ 28 ].…”

Section: Discussionsupporting

confidence: 91%

MiR-200a ameliorates peritoneal fibrosis and functional deterioration in a rat model of peritoneal dialysis

Wei

Zhan

et al. 2019

Int Urol Nephrol

View full text Add to dashboard Cite

Peritoneal fibrosis is recognised as the main cause of the technical failure of peritoneal dialysis (PD), and currently, there are no specific and effective anti-fibrosis therapies. We have found that miR-200a is down-regulated in a rat model of PD-related peritoneal fibrosis (PF) and could inhibit transforming growth factor beta 1 (TGF-β1)-induced epithelial-mesenchymal transition (EMT) in peritoneal mesothelial cells by target ZEB1/2. However, its treatment role in vivo is still largely unclear. In this study, we examined the therapeutic potential for miR-200a on PD-related PF in a rat model of PD induced by daily infusion of 4.25% dextrose-containing dialysate. Male Sprague–Dawley rats were divided into four groups: control group, PD group, PD + miR-agomir-NC group, and PD + miR-200a-agomir group ( n = 5 in each group). MiR-200a agomir was delivered into the peritoneum by intra-peritoneal injection on days 10 and 20 after PD. We found that treatment with miR-200a agomir significantly reduced the collagen volume fraction (CVF) of the peritoneum and prevented peritoneal dysfunction. The up-regulation of the EMT marker (decreased E-cadherin and increased α-smooth muscle actin) and extracellular matrix (fibronectin and collagen I) was significantly ameliorated by miR-200a in the PD + miR-200a-agomir group. Furthermore, we demonstrated that miR-200a inhibition of PF in vivo was associated with the suppression of ZEB1 and 2, which were proved to be the target of miR-200a in our previous study. In conclusion, results from the present study suggest that treatment with miR-200a may represent a novel and effective therapy for PD-related PF.

show abstract

“…Simonian and Liang et al reported that IL-22 protected against Bacillus subtilis- and bleomycin-induced lung fibrosis in mice, respectively [ 9 , 20 ]. In liver fibrosis, although Wu et al found that IL-22 activated hepatic stellate cells and mediated fibrogenesis in patients with hepatitis C [ 21 ]; most studies reported a protective role of IL-22 in liver fibrosis [ 22 , 23 ]. In the cardiovascular system, Rattik et al found that knockout of IL-22 reduced the collagen area of aortic roots in atherosclerosis in mice [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Anti-Interleukin-22-Neutralizing Antibody Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Mice

Liu

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

Background Interleukin- (IL-) 22 is considered a proinflammatory cytokine. Recent evidence has demonstrated that it plays a role in cardiovascular diseases. In the recent study, we investigate whether IL-22 is involved in cardiac hypertrophy. Methods Angiotensin II was used to build hypertrophy model and the IL-22 and IL-22 receptor 1 (IL-22R1) levels in heart tissue were measured. In addition, angiotensin II-treated mice received an injection of anti-IL-22-neutralizing antibody (nAb) to investigate the effects of IL-22 nAb on myocardial hypertrophy, cardiac function, and cardiac fibrosis; the activation of the signaling pathway and the prohypertrophic inflammatory cytokine mRNA levels was detected. Furthermore, the effect of IL-22 nAb on angiotensin II-induced hypertrophy in vitro was also determined. Results IL-22 and IL-22R1 levels were significantly increased after angiotensin II infusion. Anti-IL-22 nAb significantly alleviated the severity of hypertrophy, prevented systolic and diastolic abnormalities, reduced cardiac fibrosis, STAT3 and ERK phosphorylation, and downregulated the mRNA expression of IL-17, IL-6, IL-1β, IFN-γ, and TNF-α. In addition, IL-22 nAb attenuated angiotensin II-induced hypertrophy in H9C2 cells. Conclusion Our data demonstrated that neutralization of IL-22 alleviated angiotensin II-induced cardiac hypertrophy. The downregulation of IL-22 may be a novel therapeutic strategy to prevent cardiac hypertrophy.

show abstract

Interleukin-22 ameliorates liver fibrosis through miR-200a/beta-catenin

Cited by 42 publications

References 28 publications

microRNA‐200a: A stage‐dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients

microRNA‐200a: A stage‐dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients

MiR-200a ameliorates peritoneal fibrosis and functional deterioration in a rat model of peritoneal dialysis

Anti-Interleukin-22-Neutralizing Antibody Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Mice

Contact Info

Product

Resources

About